Skip to the main content.
Other Therapy Areas

Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.

Learn More →

1 min read

Talk Outsourcing Strategies with Veristat at the Chief Medical Officer Summit West

Talk Outsourcing Strategies with Veristat at the Chief Medical Officer Summit West

CMO Summit West 2015

Join Veristat at the 3rd Annual Chief Medical Officer Summit West, which is said to be "the only conference of its kind dedicated to addressing the unique challenges faced by CMOs in emerging biotechnology firms".

In addition to addressing the ever-changing role of the Chief Medical Officer, the CMO Summit will cover many topics that Veristat is well-versed in, including:

  • Measurement of Treatment Benefit in an Era of Patient-Focused Drug Development
  • Designing and Implementing Clinical Development Plans for Small Biotechs
  • Challenges with Patient Recruitment for CMOs and How They Can Overcome Them
  • CRO Management: Best Practices for Small Biotech Firms
  • Latest Clinical Development Approaches for CMOs
  • Creating Financial Value with Adaptive Trials - Moving Beyond Theory and Into Practice

As a full-service CRO, Veristat is extremely experienced in working with Chief Medical Officers.   Meet with us to learn why.   

Meet with David Stark or Naeiry Vartevan at the CMO Summit West. Even if you are not attending, reach out today to schedule a meeting.

SCHEDULE MEETING

Talk CRO Outsourcing Strategies with Veristat at OCT East

Talk CRO Outsourcing Strategies with Veristat at OCT East

Talk CRO Outsourcing Strategies with Veristat at OCT East

Read More
Veristat's President Speaks at 3rd Annual Chief Medical Officer Summit

Veristat's President Speaks at 3rd Annual Chief Medical Officer Summit

Veristat's President, John Balser, PhD, discusses the key factors in building successful clinical trials at the 3rd Annual Chief Medical Officer...

Read More
Project Optimus Explained: Why the FDA is Shifting Away from Maximum Tolerated Dose in Oncology

Project Optimus Explained: Why the FDA is Shifting Away from Maximum Tolerated Dose in Oncology

Historically, oncology drug development followed a straightforward principle: identify the highest dose patients could tolerate without unacceptable...

Read More